Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527114 | 0.86 | ALDH1A1 (0.51) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL6609952 | 0.83 | ALDH1A1 (0.49) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL11092415 | 0.82 | MAPT (0.48) | KMT2AALDH1A1MAPTRAB9ALMNA | |
| SCHEMBL1345244 | 0.82 | KMT2A (0.56) | KMT2AMAPTRAB9AGAALMNA | |
| SCHEMBL1345434 | 0.82 | KMT2A (0.56) | KMT2AMAPTRAB9AGAALMNA | |
| SCHEMBL427393 | 0.82 | KMT2A (0.56) | KMT2AMAPTRAB9AGAALMNA | |
| SCHEMBL11090216 | 0.81 | ALDH1A1 (0.47) | KMT2AALDH1A1KDM4EMAPTGAA | |
| SCHEMBL2761732 | 0.81 | SLC6A3 (0.48) | KMT2AALDH1A1KDM4EMAPTGAA | |
| SCHEMBL2761873 | 0.80 | ALDH1A1 (0.46) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL4136472 | 0.79 | ALDH1A1 (0.58) | KMT2AALDH1A1KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11714080-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11714080-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11692998-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-11692998-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210215670-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2021-07-15 | — | — | US | disclosed |
| US-20210215671-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2021-07-15 | — | — | US | disclosed |
| US-10955408-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200049693-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2020-02-13 | — | — | US | disclosed |
| US-10473643-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10018619-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HHS (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090275070-A1 | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | HOUSEY GERARD M | 2009-11-05 | — | — | US | disclosed |
| US-20090275070-A1 | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | HOUSEY GERARD M | 2009-11-05 | — | — | US | disclosed |
| EP-2027088-A2 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008091681-A2 | THERAMUTEIN MODULATORS | HOUSEY GERARD M (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070111199-A1 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC | 2007-05-17 | — | — | US | disclosed |
| US-20070111199-A1 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC | 2007-05-17 | — | — | US | disclosed |
| US-4476315-A | NITROARYLACETIC ACID ESTERS FROM NITROAROMATIC COMPOUNDS | ETHYL CORPORATION (US) | 1984-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312323-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | KMT2A 1048/4885ALDH1A1 1547/4885KDM4E 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.